Diagnosis and biomarkers of predementia in Alzheimer's disease

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Forlenza, Orestes V ^a   Diniz, Breno S ^a   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITION; DEMENTIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PREDICTION; REVIEW; TRANSLATIONAL RESEARCH; BRAIN; CHEMISTRY; RADIOGRAPHY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CEREBROSPINAL FLUID; DEMENTIA; EARLY DIAGNOSIS; HUMANS;

EID: 78650413213     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-89     Document Type: Review

References (114)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342. 10.2105/AJPH.88.9.1337, 1509089, 9736873.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191. 10.1016/j.jalz.2007.04.381, 19595937.
3. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement 2008, 4:316-323. 10.1016/j.jalz.2008.05.2479, 18790458.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
5. McKhann G, Hyman B, Jack C, Kawas C, Klunk W, Knopman D, Koroshetz W, Manly J, Mayeux R, Mohs R, Morris J, Weintraub S, . Alzheimer's Disease Dementia Workgroup Criteria for AD dementia. Alzheimer's Disease Dementia Workgroup., http://www.alz.org/research/diagnostic_criteria/dementia_recommendations.pdf
6. Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N, Gamst A, Holtzman D, Jagust W, Petersen R, Snyder P, . Mild Cognitive Impairment due to Alzheimer's Disease Workgroup Criteria for mild cognitive impairment due to Alzheimer's disease. Mild Cognitive Impairment due to Alzheimer's Disease Workgroup., http://www.alz.org/research/diagnostic_criteria/mci_reccomendations.pdf
7. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009, 68:1-14. 10.1097/NEN.0b013e3181919a48, 2692822, 19104448.
8. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128. 10.1016/S1474-4422(09)70299-6, 2819840, 20083042.
9. Blass JP. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging 2002, 23:1077-1084. 10.1016/S0197-4580(02)00036-2, 12470805.
10. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H. Sequence of Aβ-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000, 59:733-748.
11. Thal DR, Rüb U, Orantes M, Braak H. Phases of A β-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
12. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003, 62:1087-1095.
13. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475. 10.1001/archneurol.2009.269, 2798814, 20008650.
14. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308. 10.1001/archneur.56.3.303, 10190820.
15. Forlenza OV, Chiu E. Mild cognitive impairment: a concept ready to move on?. Cur Opin Psychiatry 2008, 21:529-532.
16. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006, 63:665-672. 10.1001/archneur.63.5.665, 16682536.
17. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäckman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol 2000, 57:839-844. 10.1001/archneur.57.6.839, 10867781.
18. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007, 64:862-871. 10.1001/archneur.64.6.862, 17562935.
19. Parra MA, Abrahams S, Fabi K, Logie R, Luzzi S, Della Sala S. Short term memory binding deficits in Alzheimer's disease. Brain 2009, 132:1057-1066. 10.1093/brain/awp036, 19293236.
20. Forlenza OV, Diniz BS, Nunes PV, Memoria CM, Yassuda MS, Gattaz WF. Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr 2009, 21:1088-1095. 10.1017/S1041610209990792, 19691909.
21. Pereira FS, Yassuda MS, Oliveira AM, Forlenza OV. Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment. Int Psychogeriatr 2008, 20:1104-1115. 10.1017/S1041610208007631, 18752698.
22. Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C, . Medical Research Council Cognitive Function and Aging Study Early cognitive change in the general population: how do different definitions work?. J Am Geriatr Soc 2007, 55:1534-1540. 10.1111/j.1532-5415.2007.01386.x, 17908056, Medical Research Council Cognitive Function and Aging Study.
23. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
24. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240-246. 10.1111/j.1365-2796.2004.01380.x, 15324367.
25. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004, 16:129-140. 10.1017/S1041610204000092, 15318760.
26. Mitchell A, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009, 119:252-265. 10.1111/j.1600-0447.2008.01326.x, 19236314.
27. Visser P, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J Neurol Neurosurg Psychiatry 2005, 76:1348-1354. 10.1136/jnnp.2004.047720, 1739362, 16170074.
28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194. 10.1111/j.1365-2796.2004.01388.x, 15324362.
29. Busse A, Hansel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006, 67:2176-2185. 10.1212/01.wnl.0000249117.23318.e1, 17190940.
30. Fischer P, Jungwirth S, Zehetmayer S, Weiss-gram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH. Conversion of subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007, 68:288-291. 10.1212/01.wnl.0000252358.03285.9d, 17242334.
31. Palmer K, Wang HX, Bäckman L, Winblad B, Fratiglioni L. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen project. Am J Psychiatry 2002, 159:436-442. 10.1176/appi.ajp.159.3.436, 11870008.
32. Loewenstein DA, Acevedo A, Agron J, Duara R. Stability of neurocognitive impairment in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 23:82-86. 10.1159/000097304, 17124415.
33. Diniz BS, Nunes PV, Yassuda MS, Forlenza O. Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. Dement Geriatr Cogn Disord 2009, 27:224-231. 10.1159/000203346, 19225236.
34. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 2007, 165:1231-1238. 10.1093/aje/kwm085, 2516202, 17431012.
35. Burton CL, Strauss E, Bunce D, Hunter MA, Hultsch DF. Functional abilities in older adults with mild cognitive impairment. Gerontology 2009, 55:570-581. 10.1159/000228918, 19602873.
36. Kim KR, Lee KS, Cheong HK, Eom JS, Oh BH, Hong CH. Characteristic profiles of instrumental activities of daily living in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 27:278-285. 10.1159/000204765, 19246913.
37. Wadley VG, Okonkwo O, Crowe M, Ross-Meadows LA. Mild cognitive impairment and everyday function: evidence of reduced speed in performing instrumental activities of daily living. Am J Geriatr Psychiatry 2008, 16:416-424.
38. Jefferson AL, Byerly LK, Vanderhill S, Lambe S, Wong S, Ozonoff A, Karlawish JH. Characterization of activities of daily living in individuals with mild cognitive impairment. Am J Geriatr Psychiatry 2008, 16:375-383. 10.1097/JGP.0b013e318162f197, 2682324, 18332397.
39. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A. Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry 2007, 22:1217-1222. 10.1002/gps.1816, 17562522.
40. Jorm AF. Assessment of cognitive impairment and dementia using informant report. Clin Psychol Rev 1996, 16:51-73.
41. Abreu ID, Nunes PV, Diniz BS, Forlenza OV. Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil. Rev Bras Psiquiatr 2008, 30:346-349.
42. Pereira FS, Yassuda MS, Oliveira AM, Diniz BS, Radanovic M, Talib LL, Gattaz WF, Forlenza OV. Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. J Int Neuropsychol Soc 2010, 16:297-305. 10.1017/S1355617709991330, 20175938.
43. Pereira FS, Oliveira AM, Diniz BS, Forlenza OV, Yassuda MS. Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. Arch Clin Neuropsychol 2010, 25:335-343. 10.1093/arclin/acq029, 20484096.
44. Wagner JA. Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 2009, 86:3-7. 10.1038/clpt.2009.77, 19536113.
45. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001, 310:173-186. 10.1016/S0009-8981(01)00573-3, 11498083.
46. Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005, 6:69-84. 10.1080/15622970510029786, 16156480.
47. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041. 10.1093/brain/awl269, 17012293.
48. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 2003, 60:1696-1702. 10.1001/archneur.60.12.1696, 14676043.
49. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389. 10.1001/archneurol.2008.596, 19273758.
50. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613. 10.1016/S1474-4422(03)00530-1, 14505582.
51. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-34. 10.1016/S1474-4422(06)70355-6, 16488378.
52. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373-379. 10.1001/archneur.58.3.373, 11255440.
53. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002, 59:1729-1734. 10.1001/archneur.59.11.1729, 12433260.
54. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H, Imahori K. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000, 166:201-203. 10.1006/exnr.2000.7501, 11031097.
55. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004, 9:705-710.
56. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, . Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413. 10.1002/ana.21610, 2696350, 19296504, Alzheimer's Disease Neuroimaging Initiative.
57. Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF. Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 2010, 32:216-222. 10.1590/S1516-44462010005000002, 20414590.
58. Diniz B, Pinto J, Forlenza OV. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008, 9:172-182. 10.1080/15622970701535502, 17886169.
59. Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem lab Med 2010, 48:603-607. 10.1515/CCLM.2010.131, 20201744.
60. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144. 10.1038/nrneurol.2010.4, 20157306.
61. Santos AN, Torkler S, Nowak D, Schlittig C, Goerdes M, Lauber T, Trischmann L, Schaupp M, Penz M, Tiller FW, Böhm G. Detection of amyloid-β oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J Alzheimers Dis 2007, 11:117-125.
62. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 2010, 24:2716-2726. 10.1096/fj.09-150359, 20339023.
63. Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE. Oligomerization partially explains the lowering of Aβ42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis 2009, 6:139-147. 10.1159/000225376, 19521063.
64. Busatto GF, Diniz BS, Zanetti MV. Voxel-based morphometry in Alzheimer's disease. Expert Rev Neurother 2008, 8:1691-1702. 10.1586/14737175.8.11.1691, 18986240.
65. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain 2006, 129:2867-2873. 10.1093/brain/awl274, 17018552.
66. Seo SW, Im K, Lee JM, Kim YH, Kim ST, Kim SY, Yang DW, Kim SI, Cho YS, Na DL. Cortical thickness in single-versus multiple-domain amnestic mild cognitive impairment. NeuroImage 2007, 36:289-297. 10.1016/j.neuroimage.2007.02.042, 17459730.
67. Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain 2006, 129:2885-2893. 10.1093/brain/awl256, 17008332.
68. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 2009, 132:2026-2035. 10.1093/brain/awp091, 2714059, 19416949.
69. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC, . Mild cognitive impairment Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377. Mild cognitive impairment.
70. Chetelat G, Eustache F, Viader F, De La Sayette V, Pölerin A, Mäzenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005, 11:14-25. 10.1080/13554790490896938, 15804920.
71. Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hänninen T, Pihlajamäki M, Laakso MP, Hallikainen M, Hämäläinen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol Aging 2008, 29:31-38. 10.1016/j.neurobiolaging.2006.09.007, 17097769.
72. Hämäläinen A, Tervo S, Grau-Olivares M, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hänninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala EL, Nissinen A, Vanninen R, Soininen H. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. NeuroImage 2007, 37:1122-1131.
73. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006, 5:828-834. 10.1016/S1474-4422(06)70550-6, 16987729.
74. Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. Neurobiol Aging
75. Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1994, 21:1052-1060. 10.1007/BF00181059, 7828614.
76. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, Mielke R, Kalbe E, Zändorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002, 17:302-316. 10.1006/nimg.2002.1208, 12482085.
77. Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, Dessi B, Larsson SA, Rodriguez G, Pagani M. Principal component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol Imaging 2008, 35:2191-2202. 10.1007/s00259-008-0869-z, 18648805.
78. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008, 49:390-398. 10.2967/jnumed.107.045385, 18287270.
79. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
80. Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. NeuroImage 2005, 27:934-946. 10.1016/j.neuroimage.2005.05.015, 15979341.
81. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63:2332-2340.
82. DeLeon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001, 98:10966-10971. 10.1073/pnas.191044198, 58582, 11526211.
83. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005, 46:1625-1632.
84. Mathis C, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk W. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46:2740-2754. 10.1021/jm030026b, 12801237.
85. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319. 10.1002/ana.20009, 14991808.
86. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135. 10.1016/S1474-4422(08)70001-2, 18191617.
87. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. New Engl J Med 2006, 355:2652-2663. 10.1056/NEJMoa054625, 17182990.
88. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508. 10.1212/01.wnl.0000244749.20056.d4, 17065593.
89. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 2006, 59:512-519. 10.1002/ana.20730, 16372280.
90. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009, 1:371-380. 10.1002/emmm.200900048, 2806678, 20049742.
91. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606. 10.1212/01.wnl.0000260969.94695.56, 17485647.
92. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langström B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465. 10.1016/j.neurobiolaging.2007.03.029, 17499392.
93. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760. 10.1212/WNL.0b013e3181b23564, 2830881, 19587325.
94. Villemagne V, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008, 46:1688-1697. 10.1016/j.neuropsychologia.2008.02.008, 18343463.
95. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517. 10.1001/archneur.65.11.1509, 2636844, 19001171.
96. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF. Longitudinal cognitive decline is associated with fibrillar amyloid-β measured by [11C]PiB. Neurology 2010, 74:807-815. 10.1212/WNL.0b013e3181d3e3e9, 20147655.
97. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106:6820-6825. 10.1073/pnas.0900345106, 2665196, 19346482.
98. Fagan A, Roe CM, Xiong C, Mintun MA, Morris J, Holtzman D. Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349. 10.1001/archneur.64.3.noc60123, 17210801.
99. Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, Möller MJ. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004, 56:279-283. 10.1016/j.biopsych.2004.05.014, 15312816.
100. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007, 28:1070-1074. 10.1016/j.neurobiolaging.2006.05.006, 16782233.
101. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008, 63:204-212. 10.1002/ana.21223, 2735194, 17894374.
102. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009, 30:165-173. 10.1016/j.neurobiolaging.2007.06.009, 17646035.
103. J Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, . the Alzheimer's Disease Neuroimaging Initiative Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. 10.1093/brain/awp062, 2677798, 19339253, the Alzheimer's Disease Neuroimaging Initiative.
104. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ, Jennings RG, Karow D, Dale AM, . the Alzheimer's Disease Neuroimaging Initiative Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol 2010, 31:347-354. 10.3174/ajnr.A1809, 2821467, 20075088, the Alzheimer's Disease Neuroimaging Initiative.
105. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007, 24:118-124. 10.1159/000105017, 17622715.
106. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010, 67:217-223. 10.1001/archneurol.2009.316, 20142530.
107. Sperling R, Beckett L, Bennett D, Craft S, Fagan A, Kaye J, Montine T, Park D, Reiman E, Siemers E, Stern Y, Yaffe K, . Preclinical Alzheimer's Disease Workgroup Criteria for preclinical Alzheimer's disease. Preclinical Alzheimer's Disease Workgroup., http://www.alz.org/research/diagnostic_criteria/preclinical_recommendations.pdf
108. Riley KP, Snowdon DA, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 2002, 51:567-577. 10.1002/ana.10161, 12112102.
109. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746. 10.1016/S1474-4422(07)70178-3, 17616482.
110. Petersen RC, Knopman DS. MCI is a clinically useful concept. Int Psychogeriatr 2006, 18:394-314.
111. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010, 9:387-398. 10.1038/nrd2896, 20431570.
112. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ, . National Institute on Aging Biological Markers Working G Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003, 24:521-536. 10.1016/S0197-4580(03)00002-2, 12714109, National Institute on Aging Biological Markers Working G.
113. Mortimer JA, Petersen RC. Detection of prodromal Alzheimer's disease. Ann Neurol 2008, 64:479-480. 10.1002/ana.21552, 19067352.
114. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002, 23:213-231. 10.1146/annurev.publhealth.23.100901.140525, 11910061.